Wahed FTSE USA Shariah ETF vs Nuvation Bio Inc. Class A Common Stock — how do they compare? Wahed FTSE USA Shariah ETF trades at $76.99 (market cap $1.00B), while Nuvation Bio Inc. Class A Common Stock trades at $5.22 (market cap $1.74B). The key difference: Nuvation Bio Inc. Class A Common Stock is the larger of the two by market cap, and Wahed FTSE USA Shariah ETF is trading nearer its 52-week high, Nuvation Bio Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Wahed FTSE USA Shariah ETF for 65 Days and Nuvation Bio Inc. Class A Common Stock for 0 Days on average.
| HLAL | NUVB | |
|---|---|---|
Market Cap | $1.00B | $1.74B |
Volume | 51,137 | 9,289,619 |
Sector | Sector/Thematic | Health |
52-Week High | $76.54 | $9.54 |
52-Week Low | $57.46 | $3.41 |
Typical Hold Time | 65 Days | 0 Days |
Enterprise Value | — | $1.33B |
Signals from Pluang's Aura AI — not financial advice
HLAL trades at $76.44, down 0.13% with limited daily movement. The technical picture shows bullish momentum with strong moving average support, though RSI levels above 70 indicate potential overbought conditions. Support and resistance cluster tightly around $76-77, suggesting a critical price zone. Recent corporate actions include a $0.10 dividend scheduled for September 2026.
The stock faces valuation uncertainty with key financial ratios unavailable, requiring deeper fundamental analysis. Technical strength supports near-term upside, but overbought signals and lack of current financial metrics present investment challenges. Investors need updated earnings reports and analyst coverage to assess the company's financial health and growth prospects accurately.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
HLAL is an ETF that invests in Shariah-compliant US companies. It follows a rigorous screening process to exclude businesses involved in non-compliant activities like interest-based finance, alcohol, and gambling.
Read more on HLAL →Nuvation Bio Inc. is a biopharmaceutical company focused on oncology, developing novel cancer treatments including taletrectinib (marketed as IBTROZI), a ROS1 inhibitor, and safusidenib, a brain-penetrant IDH1 inhibitor.
Read more on NUVB →